Literature DB >> 8703217

Regulation of integrin function by the urokinase receptor.

Y Wei1, M Lukashev, D I Simon, S C Bodary, S Rosenberg, M V Doyle, H A Chapman.   

Abstract

Integrin function is central to inflammation, immunity, and tumor progression. The urokinase-type plasminogen activator receptor (uPAR) and integrins formed stable complexes that both inhibited native integrin adhesive function and promoted adhesion to vitronectin via a ligand binding site on uPAR. Interaction of soluble uPAR with the active conformer of integrins mimicked the inhibitory effects of membrane uPAR. Both uPAR-mediated adhesion and altered integrin function were blocked by a peptide that bound to uPAR and disrupted complexes. These data provide a paradigm for regulation of integrins in which a nonintegrin membrane receptor interacts with and modifies the function of activated integrins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8703217     DOI: 10.1126/science.273.5281.1551

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  174 in total

Review 1.  Caveolins, liquid-ordered domains, and signal transduction.

Authors:  E J Smart; G A Graf; M A McNiven; W C Sessa; J A Engelman; P E Scherer; T Okamoto; M P Lisanti
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

2.  Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo.

Authors:  G van der Pluijm; B Sijmons; H Vloedgraven; C van der Bent; J W Drijfhout; J Verheijen; P Quax; M Karperien; S Papapoulos; C Löwik
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

3.  Functional convergence of signalling by GPI-anchored and anchorless forms of a salamander protein implicated in limb regeneration.

Authors:  Robert A Blassberg; Acely Garza-Garcia; Azara Janmohamed; Phillip B Gates; Jeremy P Brockes
Journal:  J Cell Sci       Date:  2010-11-30       Impact factor: 5.285

4.  Design, synthesis, biochemical studies, cellular characterization, and structure-based computational studies of small molecules targeting the urokinase receptor.

Authors:  Fang Wang; W Eric Knabe; Liwei Li; Inha Jo; Timmy Mani; Hartmut Roehm; Kyungsoo Oh; Jing Li; May Khanna; Samy O Meroueh
Journal:  Bioorg Med Chem       Date:  2012-06-12       Impact factor: 3.641

5.  VEGF-induced endothelial cell migration requires urokinase receptor (uPAR)-dependent integrin redistribution.

Authors:  Revu Ann Alexander; Gerald W Prager; Judit Mihaly-Bison; Pavel Uhrin; Stefan Sunzenauer; Bernd R Binder; Gerhard J Schütz; Michael Freissmuth; Johannes M Breuss
Journal:  Cardiovasc Res       Date:  2012-01-26       Impact factor: 10.787

6.  Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer.

Authors:  Peter Büchler; Howard A Reber; James S Tomlinson; Oliver Hankinson; Georgis Kallifatidis; Helmut Friess; Ingrid Herr; Oscar J Hines
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

Review 7.  Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.

Authors:  Lea M Beaulieu; Brandi R Whitley; Theodore F Wiesner; Sophie M Rehault; Diane Palmieri; Abdel G Elkahloun; Frank C Church
Journal:  Bioessays       Date:  2007-10       Impact factor: 4.345

8.  A dual role for caveolin-1 in the regulation of fibronectin matrix assembly by uPAR.

Authors:  Elizabeth Monaghan-Benson; Cynthia Corley Mastick; Paula J McKeown-Longo
Journal:  J Cell Sci       Date:  2008-10-28       Impact factor: 5.285

9.  Urokinase type plasminogen activator receptor expression in colorectal neoplasms.

Authors:  S Suzuki; Y Hayashi; Y Wang; T Nakamura; Y Morita; K Kawasaki; K Ohta; N Aoyama; S R Kim; H Itoh; Y Kuroda; W F Doe
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

10.  Urokinase and the intestinal mucosa: evidence for a role in epithelial cell turnover.

Authors:  P R Gibson; I Birchall; O Rosella; V Albert; C F Finch; D H Barkla; G P Young
Journal:  Gut       Date:  1998-11       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.